Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

Body mass index (BMI) may not provide the most accurate screening for skeletal muscle deficits among youth with pediatric‐onset inflammatory bowel disease (IBD), according to a study in the Journal of ...

The US FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

GLP-1 RA treatment was linked to 8 fewer AHI events per hour among individuals with elevated body weight and moderate to severe OSA who did not have diabetes. Glucagon-like peptide-1 receptor agonists ...

The FDA is implementing an enhanced review process for food chemicals currently available on the US market, with a particular focus on those that have raised consumer concerns. HealthDay News — The ...

Rates of major complications or comorbidity for Hispanic and Native American vs White hospital inpatients improved as inpatient Hispanic and Native American diversity increased. Hospital inpatient ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...